All In Biotech

Drug Trial Radar · NCT07482813

An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

An Open Label Extension, Multi-Center Study to Evaluate the Safety of SD 101 Cream in Subjects With Epidermolysis Bullosa

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 15, 2026

Primary completion

Sep 19, 2027

Study completion Oct 19, 2027

Sponsor

Lead sponsor
Paradigm TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 28 days, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to characterize the continued safety of SD-101 cream containing 6% allantoin in the treatment of the skin in patients with Simplex, Recessive Dystrophic, or JEB-nH EB.

Conditions

  • Epidermolysis Bullosa (EB)

Interventions

  • SD-101 Dermal Cream (6%)Drug

    SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measuring safety of SD-101-6.0Time frame: 1 Year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.